Drug interactions with diosmectite: a study using the artificial stomach-duodenum model

被引:39
作者
Castela-Papin, N
Cai, S
Vatier, J
Keller, F
Souleau, CH
Farinotti, R [1 ]
机构
[1] Univ Paris 11, Fac Pharm, Lab Pharm Clin, F-92296 Chatenay Malabry, France
[2] Univ Paris 05, Fac Pharm, Lab Biomath, F-75006 Paris, France
[3] Univ Paris 11, Fac Pharm, Lab Chim Phys Minerale & Bioinorgan, F-92296 Chatenay Malabry, France
关键词
drug-clay interaction; clay; diosmectite; pK(a);
D O I
10.1016/S0378-5173(99)00073-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug interactions with diosmectite, a gastric-protective drug, were studied in vitro using an artificial stomach-duodenum model. The behavior of neutral and ionisable drugs with pK(a) values ranging between 2 and 8 was monitored to determine the physicochemical characteristics of the interactions. The main neutral (digoxin) and acid (valproic acid) drug substances were moderately fixed by clay (<27%), in a pH-independent manner. Basic compounds with a pK(a) <7 (dapsone, metronidazole, cimetidine) were strongly fixed in acid medium (>62%), and fully released under neutral conditions. Amphoteric (fluoroquinolones) and basic compounds with a pK(a) greater than or equal to 7 (ranitidine, pyrimethamine) were adsorbed by more than 81% by diosmectite in gastric and duodenal compartments. In the part of the model representing the distal duodenum, the potential site for drug absorption, only the active substances which remained positively charged (amphoteric and basic compounds) showed a large reduction (greater than or equal to 80%) in their available free fraction. lonisation of drug substances administered per os concomitantly with diosmectite plays a crucial role in these interactions. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:111 / 119
页数:9
相关论文
共 27 条
[1]   INTERACTIONS BETWEEN SMECTITE, A MUCUS STABILIZER, AND ACIDIC AND BASIC DRUGS - INVITRO AND INVIVO STUDIES [J].
ALBENGRES, E ;
URIEN, S ;
TILLEMENT, JP ;
OURY, P ;
DECOURT, S ;
FLOUVAT, B ;
DRIEU, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (05) :601-605
[2]  
BUDAVARI S, 1989, MERCK INDEX, P444
[3]  
CAILLERE S, 1982, MINERALOGIE ARGILES, V1
[4]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY METHOD FOR THE DETERMINATION OF RANITIDINE IN PLASMA [J].
CAREY, PF ;
MARTIN, LE .
JOURNAL OF LIQUID CHROMATOGRAPHY, 1979, 2 (09) :1291-1303
[5]  
CARR K, 1978, BRIT J CLIN PHARMACO, V6, P421, DOI 10.1111/j.1365-2125.1978.tb04606.x
[6]  
FREDJ G, 1986, THERAPIE, V41, P23
[7]  
FRYSENBERG MM, 1960, J SOC CHEM, V64, P224
[8]   A RAPID AND SPECIFIC SEMI-MICRO METHOD INVOLVING HIGH-PRESSURE LIQUID-CHROMATOGRAPHY FOR THE ASSAY OF METRONIDAZOLE IN PLASMA, SALIVA, SERUM, URINE AND WHOLE-BLOOD [J].
KAYE, CM ;
SANKEY, MG ;
THOMAS, LA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (05) :528-529
[9]  
KHALIL SA, 1973, PHARMAZIE, V28, P116
[10]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF NORFLOXACIN IN HUMAN-TISSUES AND PLASMA WITH FLUORESCENCE DETECTION [J].
LAGANA, A ;
CURINI, R ;
DASCENZO, G ;
MARINO, A ;
ROTATORI, M .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 417 (01) :135-142